Silence Therapeutics Plc ADR (SLN) Unusual Options Activity Today

Checking SLN unusual options activity helps you spot when traders are making outsized bets on Silence Therapeutics Plc ADR before the broader market catches on. Silence Therapeutics Plc ADR's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor SLN unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching SLN unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking SLN unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and SLN unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera.

It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Catalysts rarely arrive without a footprint, and SLN unusual options activity is often where that footprint shows up first. Our scanner tracks Silence Therapeutics Plc ADR's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at SLN unusual options volume on the call side or chasing put sweeps, Silence Therapeutics Plc ADR's unusual options flow today is one click away, so put it on your radar before the headlines hit.